111, Inc. Sponsored ADR (NASDAQ:YI - Get Free Report) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 3,700 shares, a decline of 32.7% from the May 15th total of 5,500 shares. Currently, 0.1% of the company's shares are sold short. Based on an average daily trading volume, of 20,000 shares, the short-interest ratio is currently 0.2 days.
111 Stock Performance
NASDAQ YI traded down $0.13 during trading hours on Friday, reaching $7.78. 6,129 shares of the company's stock were exchanged, compared to its average volume of 24,378. The company has a market capitalization of $67.18 million, a price-to-earnings ratio of -12.15 and a beta of 0.47. The company's 50-day moving average is $7.97 and its two-hundred day moving average is $7.57. 111 has a one year low of $4.15 and a one year high of $12.90.
111 (NASDAQ:YI - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $527.14 million for the quarter.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of 111 in a report on Wednesday, June 11th.
Read Our Latest Analysis on 111
Hedge Funds Weigh In On 111
A number of large investors have recently added to or reduced their stakes in YI. JPMorgan Chase & Co. grew its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after acquiring an additional 305,339 shares in the last quarter. FIL Ltd acquired a new position in 111 during the fourth quarter worth $450,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in 111 during the first quarter worth $92,000. Deuterium Capital Management LLC bought a new position in 111 in the first quarter valued at $81,000. Finally, Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in 111 in the 4th quarter valued at $245,000. Institutional investors own 21.32% of the company's stock.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Read More
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
